WO2006092795A3 - Oligoribonucleotides and methods of use thereof for treatment of ocular scarring and other fibrotic conditions - Google Patents

Oligoribonucleotides and methods of use thereof for treatment of ocular scarring and other fibrotic conditions Download PDF

Info

Publication number
WO2006092795A3
WO2006092795A3 PCT/IL2006/000285 IL2006000285W WO2006092795A3 WO 2006092795 A3 WO2006092795 A3 WO 2006092795A3 IL 2006000285 W IL2006000285 W IL 2006000285W WO 2006092795 A3 WO2006092795 A3 WO 2006092795A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
relates
compound
patient
oligoribonucleotides
Prior art date
Application number
PCT/IL2006/000285
Other languages
French (fr)
Other versions
WO2006092795A2 (en
Inventor
Elena Feinstein
Orna Mor
Original Assignee
Qbi Entpr Ltd
Elena Feinstein
Orna Mor
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Qbi Entpr Ltd, Elena Feinstein, Orna Mor filed Critical Qbi Entpr Ltd
Publication of WO2006092795A2 publication Critical patent/WO2006092795A2/en
Publication of WO2006092795A3 publication Critical patent/WO2006092795A3/en
Priority to IL185567A priority Critical patent/IL185567A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention relates to a double-stranded compound, preferably an oligoribonucleotide (siRNA), which down-regulates the expression of a human MMP gene at the post-transcriptional level. The invention also relates to a pharmaceutical composition comprising the compound, or a vector capable of expressing the oligoribonucleotide compound, and a pharmaceutically acceptable carrier. The present invention also contemplates a method of treating a patient suffering from a fibrotic disease such as pulmonary, kidney and liver fibrosis or ocular scarring comprising administering to the patient the pharmaceutical composition in a therapeutically effective dose so as to thereby treat the patient. The invention also relates to treatment of fibrotic and other diseases by use of antibodies to MMP polypeptide.
PCT/IL2006/000285 2005-03-01 2006-03-01 Oligoribonucleotides and methods of use thereof for treatment of ocular scarring and other fibrotic conditions WO2006092795A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
IL185567A IL185567A0 (en) 2005-03-01 2007-08-28 Oligoribonucleotides and methods of use thereof for treatment of ocular scarring and other fibrotic conditions

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65755505P 2005-03-01 2005-03-01
US60/657,555 2005-03-01

Publications (2)

Publication Number Publication Date
WO2006092795A2 WO2006092795A2 (en) 2006-09-08
WO2006092795A3 true WO2006092795A3 (en) 2007-03-01

Family

ID=36941556

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IL2006/000285 WO2006092795A2 (en) 2005-03-01 2006-03-01 Oligoribonucleotides and methods of use thereof for treatment of ocular scarring and other fibrotic conditions

Country Status (1)

Country Link
WO (1) WO2006092795A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2323736A1 (en) * 2008-09-09 2011-05-25 University of East Anglia Treatment of fibrotic eye disorders using an mmp2 inhibitor
WO2015095750A1 (en) * 2013-12-20 2015-06-25 Dow Agrosciences Llc Rnapii-140 nucleic acid molecules that confer resistance to coleopteran pests
CN107073294A (en) * 2014-09-05 2017-08-18 阿克赛医药公司 Use the method for targeting TYR or MMP1 exonuclease treatment aging and skin disorder

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BABA ET AL.: "Glycine-Extended Gastrin Induces Matrix Metalloproteinase-1- and -3-Mediated Invasion of Human Colon Cancer Cells Through Type I Collegen Gel and Matrigel", CANCER, vol. 111, 2004, pages 23 - 31, XP003007481 *
FUCHS ET AL.: "Effect of Tumor-Associated Mutant E-cadherin Variants With Defects in Exons 8 or 9 on Matrix Metalloproteinase 3", JOURNAL OF CELLULAR PHYSIOLOGY, vol. 202, 2005, pages 805 - 813, XP003007482 *
MUKHIN ET AL.: "Collagenase-2 and 3-Mediate Epidermal Growth Factor Receptor Transactivation by Bradykin b2 Receptor in Kidney Cells", THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, vol. 318, no. 3, 2006, pages 1033 - 1043, XP008076548 *
SAUNDERS ET AL.: "MMP-1 Activation By Serine Protease and MMP-10 Induces Human Capillary Tubular Network Collapse and Regression in 3D Collegen Matrices", JOURNAL OF CELL SCIENCE, vol. 118, 2005, pages 2325 - 2340, XP003007483 *

Also Published As

Publication number Publication date
WO2006092795A2 (en) 2006-09-08

Similar Documents

Publication Publication Date Title
WO2005072057A3 (en) Oligoribonucleotides and methods of use thereof for treatment of fibrotic conditions and other diseases
WO2007029249A3 (en) Oligoribonucleotides and methods of use thereof for treatment of cardiovascular diseases
WO2006035434A3 (en) Oligoribonucleotides and methods of use thereof for treatment of alopecia, acute renal failure and other diseases
WO2005117954A3 (en) Compositions and methods for treatment of neovascular diseases
WO2007089945A3 (en) Treating diseases by targeting silt3
WO2008050329A3 (en) Novel sirnas and methods of use thereof
WO2011014255A8 (en) Treatment of crohn's disease with laquinimod
WO2006133099A3 (en) Sirna microbicides for preventing and treating viral diseases
WO2006108718B1 (en) Micro rna
WO2008066776A3 (en) Methods for treating hypercholesterolemia
WO2008036682A3 (en) Treatment of liver disorders by administration of receptor-associated protein (rap)-conjugates
WO2006123248A3 (en) Improved methods and devices for delivering a therapeutic product to the ocular sphere of a subject
WO2009055742A3 (en) Delivery of active agents
WO2006093348A3 (en) Method and composition for treating peripheral vascular diseases
WO2006034373A3 (en) Variants and chemically-modified variants of phenylalanine ammonia-lyase
WO2007117509A8 (en) High delivery rates for lipid based drug formulations, and methods of treatment thereof
WO2010036460A3 (en) Anti-cd147 antibodies, methods, and uses
WO2007091250A3 (en) Enzyme replacement therapy for treating lysosomal storage diseases
WO2012007839A3 (en) Combination pharmaceutical composition and methods of treating functional diseases or conditions of gastrointestinal tract
WO2006002096A3 (en) Low doses of l-citrulline for treating diseases
WO2008036638A3 (en) Rnai modulation of scap and therapeutic uses thereof
WO2009109616A3 (en) 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, cxrl and p40
UA106209C2 (en) Choline cocrystal of 5-[(1z,2e)-2-methyl-3-phenylpropenylidene]-4-oxo-2-thioxo-3-thiazolidine acetic acid
WO2006074182A3 (en) Growth factor therapy mobilization of stem cells into the peripheral blood
WO2006045314A3 (en) Use of a growth hormone secretatogue for increasing or maintaining lean body mass and/or for treatment of chronic obstructive pulmonary disease

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 185567

Country of ref document: IL

NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

WWW Wipo information: withdrawn in national office

Country of ref document: RU

122 Ep: pct application non-entry in european phase

Ref document number: 06711267

Country of ref document: EP

Kind code of ref document: A2

WWW Wipo information: withdrawn in national office

Ref document number: 6711267

Country of ref document: EP